Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

PRXI

Praxis Impact International ETF (PRXI)

Rating:64Neutral
Price Target:$27.00â–²(7.37% Upside)

PRXI, the Praxis Impact International ETF, has a solid overall rating driven by strong, diversified holdings like HSBC and Novartis, which show healthy financial performance, positive outlooks from earnings calls, and supportive technical trends. Healthcare leaders such as AstraZeneca and Roche also add quality, though their higher valuations and signs of potentially overbought conditions, along with mixed signals from names like SAP, slightly weigh on the fund’s rating. The main risk factor is its meaningful exposure to large, established companies where valuation and overbought technical conditions could limit future upside.

Positive Factors
Strong Year-to-Date PerformanceThe ETF has delivered positive year-to-date returns, showing it has held up reasonably well so far this year.
Leading Global Companies in Top HoldingsSeveral of the largest positions, such as ASML, Mitsubishi UFJ Financial Group, HSBC, and Siemens, have shown strong performance, helping support the fund’s overall results.
Broad International DiversificationThe fund spreads its investments across many countries including Japan, the UK, Germany, France, the U.S., and others, which helps reduce the impact of weakness in any single market.
Negative Factors
Moderately High Expense RatioThe ETF’s expense ratio is on the higher side for a passive fund, which means more of the return is eaten up by fees over time.
Mixed Performance Among Top HoldingsSome key holdings like Nestlé, SAP, and Toyota have been weak this year, which can drag on the fund’s overall performance.
Recent Short-Term WeaknessThe ETF has shown negative performance over the past month, suggesting it can be sensitive to short-term market swings.

PRXI vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%SPY+14.55%PRXI+3.19%Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
6.89M
Region
Developed Markets
Expense Ratio
0.54%
Beta
0.52
Issuer
Praxis
Inception Date
Jun 24, 2026
Dividend Yield
N/A
Asset Class
Equity
Index Tracked
No Underlying Index

PRXI Summary

Praxis Impact International ETF (PRXI) is an actively managed fund that invests in companies from developed countries outside North America, following a broad international stock market theme with a faith-based, values-driven approach. It holds well-known global names like Nestlé, Toyota, ASML, and HSBC, and spreads investments across many regions such as Japan, the UK, and Europe, and across sectors like financials, healthcare, and consumer goods. Someone might invest in PRXI to gain international diversification while aligning their money with their religious or ethical values. A key risk is that international stocks can go up and down with global markets and currency changes.

How much will it cost me?

This ETF has an expense ratio of 0.54%, which means you’ll pay about $5.40 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because PRXI is actively managed and uses a specialized, faith-based impact investing approach.

What would affect this ETF?

This ETF focuses on developed markets outside the U.S., so it could benefit if Europe and Japan see stronger economic growth, stable politics, and supportive central bank policies, especially for its large positions in technology, health care, and major global banks like HSBC and Mitsubishi UFJ. On the other hand, slower growth abroad, rising interest rates that hurt financials, currency swings versus the U.S. dollar, or new regulations and controversies that affect its faith-based screening or key holdings such as ASML, Roche, and Nestlé could weigh on future returns.

PRXI Top 10 Holdings

PRXI leans heavily on Europe and Japan, and its story starts with ASML, where earlier strength has cooled, leaving the chip giant more steady than soaring. Health care is a key engine: Roche and Novartis have been rising, giving the fund a solid defensive backbone, while AstraZeneca is losing steam and quietly holding returns back. Financials like HSBC and Mitsubishi UFJ are more mixed, with recent softness offset by longer‑term gains. Overall, the ETF feels broadly diversified but still anchored in European pharma and global financials.

PRXI top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
NL:ASMLNL:ASMLASML Holding NV3.01%$207.18KEUR 511.40B51.88%76Outperform
RHHVFRHHVFRoche Holding AG――――73Outperform
CH:NOVNCH:NOVNNovartis AG1.60%$110.52KCHF 245.40B26.78%80Outperform
GB:HSBAGB:HSBAHSBC Holdings1.60%$109.89KGBP 231.98B20.93%80Outperform
AZNAZNAstraZeneca――――80Outperform
CH:NESNCH:NESNNestlé SA1.38%$95.27KCHF 225.64B8.18%71Outperform
JP:8306JP:8306Mitsubishi UFJ Financial Group1.34%$92.02KJPY 39.11T41.84%76Outperform
JP:7203JP:7203Toyota Motor1.25%$86.12KJPY 40.48T6.88%80Outperform
DE:SAPDE:SAPSAP SE1.23%$84.50KEUR 249.22B-2.13%66Neutral

PRXI Technical Analysis

Technical Analysis SentimentPositive
Last Price25.15

Price Trends

50DMA25.07Positive
100DMA25.20Negative

Market Momentum

MACD0.04Negative
RSI52.39Neutral
STOCH58.91Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PRXI, the sentiment is Positive. The current price of 25.15 is above the 20-day moving average (MA) of 24.98, above the 50-day MA of 25.07, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 52.39 is Neutral, neither overbought nor oversold. The STOCH value of 58.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRXI.

PRXI Peer Comparison

Comparison Results

PRXI against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
PRXIPRXI$25.15$27.00(7.37% Upside)$6.89M0.54%64Neutral
INEQINEQ$40.27$46.14(14.58% Upside)$94.65M0.45%66Neutral
RWINRWIN$27.42$32.15(17.26% Upside)$20.53M0.42%66Neutral
LCIVLCIV$26.37―$20.46M0.99%67Neutral
FFDIFFDI$30.80$37.50(21.75% Upside)$18.53M0.55%66Neutral
JINTJINT$24.90$34.19(37.33% Upside)$9.94M0.35%67Neutral

Performance Comparison

0%10%20%PRXIINEQRWINLCIVFFDIJINTJul '26Aug '26Sep '26Oct '26Nov '26
PRXI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PRXIPraxis Impact International ETF25.150.783.19%
INEQColumbia International Equity Income Etf40.275.6316.25%
RWINRayliant NxtGen Multifactor International Equity ETF27.421.706.61%
LCIVLogan Capital International ETF26.371.546.20%
FFDIFidelity Fundamental Developed International ETF30.801.946.73%
JINTJanus Henderson International Core Alpha ETF24.90-0.27-1.05%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.